| Thanks to SoCalBio Weekly Update Sponsor |
Join us in June SoCalBio/Image 2000 Golf Classic
Title Sponsor
 Benefiting When: June 28, 2010Time: 10:00am - 8:30pm Where: Old Ranch Country Club, Seal Beach, California |
Recommended Event
Catch the Wave
April 21, 2010
3 - 7 pm
Riverside, CA
More Information
|
Join SoCalBioJoin well-known entrepreneur Alfred Mann and other SoCalBio leaders to promote the biotech and device industries in the Greater Los Angeles Metro Area for job creation and overall economic growth. |  |
|
|  Editor: Ahmed Enany
President & CEO
Southern California
Biomedical Council
(SoCalBio)
enany@socalbio.org
www.socalbio.org | April 19, 2010  |
| Featured News Story | Abraxis BioScience for Sale?
 The Los Angeles-based drug company Abraxis BioScience led by Patrick
Soon-Shiong (photo right) hired Goldman Sachs and Lazard as financial advisers to help the company weigh strategic options that could include a sale, according to numerous reports that cite people familiar with the matter.... Read more |
| Featured Analysis | Biotech IPOs On The Mend?
Seventeen years and hundreds of millions of dollars after first starting work on its new prostrate-cancer treatment, Seattle-based Dendreon may finally see a payoff on May 1. That's when the Food & Drug Administration is likely to approve
Provenge. It would be the first in a new class of treatment options known as active cellular
immunotherapy, which leverages the patient's own immune system to fight cancer. Will Dendreon's success open the IPO flood gate? .... Read more |
 |  |
| Featured Resource | Learn About the GAP Program at UCLA
  Directed by Robert Foster, (photo right), the Global Access Program (GAP) at the UCLA Anderson School of Management was founded in 1998 and has since worked with over 328 international technology companies in ten countries. GAP is a unique educational program that matches a team of students from the Fully Employed MBA
(FEMBA) program with existing international technology companies to develop a comprehensive business strategy that enables the companies to move to the next stage of their corporate development.... Learn how your company can benefit |
| RSVP Now | Trends in Ophthalmology  Exploring the frontiers of ophthalmic device innovations Speakers - Sean
Caffey, MD, CEO, Replenish, Inc. (Pasadena)
- Paul Dougherty, MD, Dougherty Laser Vision (Los Angeles)
- Robert Greenberg, MD, PhD, President & CEO, Second Sight Medical Products (Sylmar)
- Stacy
Pritt, DVM, MS, MBA, CPIA, Director & General Manager,Biological Test Center (Irvine)
- Chris
Sandstedt, Ph.D., Director of Optics Research, Calhoun Vision (Pasadena)
|
| Video Clips | SoCalBio Takes on Obesity
Access video clips of the Southern California Biomedical Council's March 25, 2010 Networking Forum in Irvine, California which featured a discussion focused on the latest medical devices for treating morbid obesity. Clip 1: http://www.youtube.com/socalbio#p/u/8/zpXPU945x-U |
| Welcome New SoCalBio Members | Modo (Beaverton, OR)
 Modo designs and builds medical carts for the most successful medical device businesses in the world... Learn more
Allied Intrade (San Marcos, CA) Allied Intrade is an OEM Manufacturers' Liaison providing custom manufacturing, logistics and global supply chain solutions to US companies engaged in the medical device area.... Learn more |
| VC Investment | Q1/2010 VC Investment Drops
 The biggest losers were life sciences companies, whose collective take fell 26% quarter-over-quarter.
Cleantech, on the other hand, rebounded with 87% more venture funding than in Q4 2009.... Read more |
| Construction | LA BioMed Wins $10M in Stimulus Grant Funding to Construct a New Research Building
Funded through the National Institutes of Health, the grant will pay for construction of a new Chronic Disease Clinical Research Center to be completed in the fall of 2013. The facility will house researchers who focus on chronic obstructive pulmonary disease
(COPD), cardiac disease and HIV/AIDS... Read more |
| Studies | Aeolus Pharmaceuticals Announces the Initiation of a Second Study of AEOL 10150 as a Medical Countermeasure for GI Acute Radiation Syndrome
Funded by
NIAID, this study is designed to test the efficacy of AEOL 10150, as measured by survival advantage, as a treatment for damage to the GI tract due to exposure to radiation. If effective, additional studies could be funded to optimize dose and duration of delivery, and to evaluate the window of opportunity for treatment after exposure.... Learn more
ABRAXANE in Combination with Gemcitabine Increases Survival in First-Line Treatment of Advanced Pancreatic Cancer in Phase I/II Study
The updated survival data were presented by the Los Angels-based Abraxis BioScience during the 101st Annual Meeting of the American Association for Cancer Research
(AACR) being held in Washington, D.C. The combination of
nab-paclitaxel (125mg/m(2)) and gemcitabine (1000 mg/m(2)) is now the treatment arm of a randomized Phase 3 clinical trial that is currently enrolling patients.... Read more
|
| Partnerships | Interventional Spine and Syndicom Partner to Provide Physicians Access to an Innovative Knowledge Share Network The partnering companies have launched the Knowledge Share Network, an on-line collaboration site for spine surgeons featuring medical case studies as an educational resource on percutaneous methods of spine treatment. The alliance aims to enhance surgeon education through the use of case studies and, as a result, help shorten procedure times, achieve lower complication rates, and minimize patient trauma.... Learn more
Beckman Coulter Signs Agreements With Premier, Inc. to Provide Medical Laboratory Instruments and Supplies
Under the terms of the three-year agreement, Premier members will continue to have access to specially negotiated pricing for automation, general chemistry, immunoassay, and integrated work cell products from Beckman Coulter. This agreement is in addition to existing agreements to purchase hematology and hemostasis products from Beckman Coulter. ... Learn more
|
| Product Approvals | Watson Pharmaceuticals' Generic Toprol XL 100 mg and 200 mg Receives FDA Approval
Toprol XL 100 and 200 mg and its generic equivalents had total U.S. sales of approximately $403 million for the twelve months ending February 2010, according to IMS Health. Metoprolol succinate extended-release is a beta-blocker used to treat angina, heart failure and high blood pressure.... Read more |
| About SoCalBio |  SoCalBio membership links you to partners, contract manufacturers, regulatory and legal experts, and policy makers. The organization's programs help emerging biotech and medical device companies grow. Membership is affordable -- as low as $500 -- and offers access to networking opportunities, advocacy, discounts through our group purchasing program group purchasing program and other benefits you simply can't find elsewhere ... Join SoCalBio |
|
|
